Möchten Sie immer auf dem neuesten Stand bleiben?

Amsterdam, The Netherlands, and Holzgerlingen, Germany, July 01, 2020, 08:30 am CEST - Curetis N.V. in liquidatie (the "Company") today announced the publication of its audited 2019 full year...

Amsterdam, The Netherlands, and Holzgerlingen, Germany, April 30, 2020, 08:00 am CET - Curetis N.V. in liquidatie (the "Company") today announced that the publication of its audited 2019 full year...

Amsterdam, the Netherlands, Holzgerlingen, Germany April 20, 2020, 8:00 am CEST - Curetis N.V. in liquidatie (the "Company") announces that the liquidators of the Company have resolved upon a...

- Following approval of shareholders, companies sign German transfer agreement - Curetis GmbH and its subsidiaries Curetis USA Inc. and Ares Genetics GmbH are now wholly owned by OpGen, Inc. -...

Quorum achieved for OpGen stockholder vote on Curetis business combination with 99% of votes supporting transactionTransaction close anticipated by early April 2020Combined OpGen and Curetis...

- Rapid real-time PCR test allows testing for SARS-CoV2 in only a few hours - Test kit to be made available via Curetis’ European sales channels - Synergies with Curetis Unyvero HPN panel for...

Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, March 10, 2020, 16:15 pm CET - Curetis N.V. (the "Company" and together with its subsidiaries "Curetis"), a developer of...

- Shareholders adopt all proposed resolutions - EGM votes clear way for closing of business combination with OpGen, Inc., subject to OpGen’s stockholders’ approval - Subsequently Curetis N.V....

                                                       Revenue increases by 64% to EUR 2.3 million, up from 1.4 million in 2018More than tripled total contract order volume received...

Exclusive distribution agreement for initial term of 3 yearsQuaphaco commits to minimum purchase totaling about EUR 1.9 million during initial term    Amsterdam, the Netherlands, San Diego, CA,...